[1][2][3][4] Based on findings from a multi-centre diagnostic accuracy assessment conducted by The Foundation for Innovative New Diagnostics (FIND), the World Health Organization (WHO) announced endorsement of Molbio's molecular assays Truenat MTB, Truenat MTB Plus and Truenat MTB RIFDx as initial diagnostic tests of pulmonary Tuberculosis and Rifampicin Resistance through a rapid communication in January,2020.
The Truenat test was incorporated in India's National Tuberculosis Elimination Programme after recommendations from the Indian Council of Medical Research (ICMR).
[5][6][7][8] The Government of Andhra Pradesh was one of the first adopter of Truenat under its Revised National Tuberculosis Control Programme (RNTCP) for TB diagnosis.
[10] The test processes oropharyngeal and nasopharyngeal swab specimen and provides results within one hour from sample collection.
[13] The devices function in a wide range of environmental conditions with minimal user input, making them suitable for use in primary healthcare settings with minimal infrastructural requirements, providing an automated reporting system and having real time data transfer capability for centralized monitoring and analytics for disease surveillance.